Search clinical trials for: ridaforolimus

Total 46 results

Medinol Ltd.

Not yet recruiting

IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System

Coronary Artery Disease | Coronary Stenosis
Medinol Ltd.

Recruiting

IonMAN Trial- First In Human Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System (IonMAN)

Cardiovascular Diseases | Coronary Disease | Non-ST Elevated Myocardial Infarction | Coronary Stenosis

Israel, Brazil
Medinol Ltd.

Completed

MedJ-01 Ridaforolimus Eluting Coronary Stent System Trial (JNIR) (JNIR)

de Novo or Restenosis Lesions

Japan
Yale University

Active, not recruiting

Torsemide Comparison With Furosemide for Management of Patients With Stable Heart Failure (TFO)

Heart Failure

United States
NCIC Clinical Trials Group
Ariad Pharmaceuticals

Completed

Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer

Endometrial Cancer

Canada
Medinol Ltd.

Completed

BIONICS - Pharmacokinetics (PK) Trial (BIONICS)

Heart Disease

United States
Medinol Ltd.

Completed

BIONICS Small Vessels Trial EluNIR Ridaforolimus Eluting Coronary Stent System (EluNIR) In Coronary Stenosis Trial

Myocardial Ischemia | Cardiovascular Diseases | Coronary Disease | Coronary Stenosis

Israel
Medinol Ltd.

Completed

EluNIR Ridaforolimus Eluting Coronary Stent System in Patients at High Bleeding Risk (HBR)- EluNIR HBR Study

Coronary Stenosis

Israel
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma

Lymphoma | Unspecified Adult Solid Tumor, Protocol Specific

United States
Angela Taber MD
The Miriam Hospital; Rhode Island Hospital; Memorial Hospital of Rhode Island; Roger...

Terminated

Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer

Non-Small Cell Lung Cancer

United States
Medinol Ltd.

Completed

BIONICS 38 mm Trial EluNIR Ridaforolimus Eluting Coronary Stent System (EluNIR) In Coronary Stenosis Trial

Coronary Stenosis

Israel
Medinol Ltd.

Completed

BIONICS Israel Trial

Stenosis

Israel
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effect of MK-8669 (Ridaforolimus) on QTc Interval in Participants With Advanced Cancer (MK-8669-037)

Metastatic or Locally Advanced Cancer
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059)

Cancer, Advanced
Merck Sharp & Dohme LLC

Completed

A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)

Breast Neoplasms
Merck Sharp & Dohme LLC

Terminated

A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056)

Solid Tumors
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Terminated

Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038)

Advanced Cancers
Merck Sharp & Dohme LLC

Terminated

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Neoplasms Malignant
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC

Completed

Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids

Ovarian Cancer | Endometrial Cancer

United States
Merck Sharp & Dohme LLC

Completed

A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)

Breast Cancer
Merck Sharp & Dohme LLC

Completed

Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)

Solid Tumors
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)

Prostate Cancer

United States
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)

Lymphoma | Multiple Myeloma | Tumors

United States
Merck Sharp & Dohme LLC

Completed

Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)

Breast Cancer | Breast Neoplasms
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)

Lymphoma | Multiple Myeloma | Tumors
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)

Advanced Cancer
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)

Prostate Cancer
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)

Lymphoma | Myelodysplastic Syndromes | Leukemia | Hematologic Malignancies | Myeloid Metaplasia

United States
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)

Glioblastoma | Malignant Glioma | Gliosarcoma

United States
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)

Sarcoma | Cancer
Merck Sharp & Dohme LLC

Completed

Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)

Endometrial Cancer
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1)

Sarcoma
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Ridaforolimus in Patients With Hepatic Insufficiency (MK-8669-046)

Hepatic Insufficiency | Healthy Volunteers
Merck Sharp & Dohme LLC

Completed

Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044)

Relapsed or Refractory Advanced Cancer
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)

Endometrial Cancer
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) (SUCCEED)

Metastatic Soft-Tissue Sarcomas | Metastatic Bone Sarcomas
Merck Sharp & Dohme LLC
University of Colorado, Denver; Memorial Sloan Kettering Cancer Center; H. Lee... and other collaborators

Completed

A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED)

Solid Tumors
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)

Sarcoma, Soft Tissue | Osteosarcoma | Leiomyosarcoma | Liposarcoma | Metastases
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)

Solid Tumor
Merck Sharp & Dohme LLC

Completed

Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)

Neoplasm
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)

Cancer
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)

Neoplasms
Merck Sharp & Dohme LLC

Completed

The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)

Breast Cancer
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Terminated

A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)

Non-Small Cell Lung Cancer
Parkway Medical Center

Terminated

A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder (OCD)

Obsessive Compulsive Disorder

United States
The University of Texas Health Science Center at...
Merck Sharp & Dohme LLC

Withdrawn

Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue Sarcoma

Soft Tissue Sarcoma

United States

3

Subscribe